Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Gyala Therapeutics
Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
Corstasis Therapeutics Announces
Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
Biomea Fusion
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and ...
Novartis returns to Monte Rosa
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Amneal secures FDA approval for sodium oxybate solution
US-based Amneal Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its 500mg/mL sodium oxybate oral solution.
LB Pharmaceuticals
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut
Artificial intelligence
Artificial intelligence accelerates drug discovery and reduces animal testing
Polyrizon
Polyrizon reports positive preclinical results for nasal allergy blocker
Apple Watch Series 11 receives FDA approval for hypertension alerts
The feature will reportedly be available in 150 countries when it starts shipping on September 19.
GTCR
GTCR to acquire generic drug maker Zentiva
Adjunctive Use Approved CBD
Study: Adjunctive Use of FDA-Approved CBD Formulation Reduces Seizures in Pediatric Patients With Rett Syndrome
Sanofi’s Tzield
Sanofi’s Tzield gains approval in China for T1D management
25
26
27
28
29
30
31
32
33